Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril-valsartan versus losartan or captopril for right ventricular function in right heart failure
IRCT20230926059524N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sacubitril + valsartan, losartan and captopril in Right heart dysfunction (RHF), ischaemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Left ventricular ejection fraction, Right ventricular dysfunction and 8 more. Started Jan 2024; status: completed.
02
Drugs
sacubitril + valsartanlosartancaptopril
03
Conditions
Right heart dysfunction (RHF)ischaemic cardiomyopathy (ICM)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on IRCT20230926059524N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230926059524N1.